Thursday, October 23, 2008
Dublin, Ireland-based contract research organization (CRO) ICON released third quarter financial results that show a 35% increase in revenues compared with the same period last year. Net revenues for the quarter were $225.5 million, compared with $166.9 million in the third quarter of 2007. Year-to-date net revenues are up 43.4% to $645.2 million, exceeding net revenues achieved in all of 2007, according to a company release. Operating profits the first nine months of 2008 were $73 million. Net income jumped 46% to $21.4 million or 35 cents per share on a diluted basis, compared with $14.5 million or 24 cents per share in the prior year’s quarter.
Clinical Trials & Surveys Corp (C-TASC), a clinical trials solutions company, will assist the U.S.Food and Drug Administration (FDA) Centers for Quality Assurance and Biostatistics to develop new methods and procedures for evaluating all New Drug Applications submitted for FDA approval. Under the $5.5 million base contract, C-TASC will use components of its StudyCTMS study management software application to customize a solution for the FDA that will standardize how clinical trial data for new therapies will be presented and reviewed. C-TASC statisticians will also work with FDA staff to perform some of the data preparations and analyses for these reviews. StudyCTMS is C-TASC’s proprietary web-based data management solution that enables clinical trials managers to easily develop and manage clinical studies and deliver the accumulated data and metadata in an easy-to-read and FDA-acceptable format.
The congressional investigation into an influential psychiatrist’s failure to disclose more than a million dollars in drugmaker payments is the latest in a spate of conflict-of-interest investigations that may force changes in the way financial disclosures are handled.
CenterWatch, a global source for clinical trials information, today announced the release of its latest report, Central and Eastern Europe: Outsourcing Trends and Growth Opportunities in Clinical Trials. The report explores the evolution of this region that has seen its growth in the industry triple in the last five years, making it the largest area for global clinical trial initiations outside of North America and Western Europe.
Dr. Paul Bleicher, chairman and founder of Waltham, Mass.-based eClinical technology company Phase Forward, will step down from his day-to-day operational responsibilities at the end of October. Phase Forward president and CEO Robert Weiler will also assume Bleicher’s role as chairman of the company’s board of directors, of which Bleicher will remain a member.